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ABSTRACT 
Purpose: Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-
1)/programmed death ligand (PD-L1) antibodies demonstrates improvements in 
treatment of advanced non-small cell lung cancer (NSCLC). Treatment stratification 
depends on immunohistochemical PD-L1 measurement of biopsy material, an 
invasive method that does not account for spatiotemporal heterogeneity. Using a 
single domain antibody (sdAb), NM-01, against PD-L1, radiolabeled site-specifically 
with technetium-99m (99mTc) for single photon emission computed tomography 
(SPECT) imaging, we aimed to assess the safety, radiation dosimetry and imaging 
characteristics of this radiopharmaceutical and correlate tumor uptake with PD-L1 
immunohistochemistry results. Methods: Sixteen patients (mean age 61.7 years, 11 
male) with NSCLC were recruited. Primary tumor PD-L1 expression was measured 
by immunohistochemistry. NM-01 was radiolabeled with 
[99mTc(OH2)3(CO)3]
+ complex binding to its C-terminal hexahistidine tag. 
Administered activity was 3.8-10.4 MBq/kg, corresponding to 100 µg or 400 µg of 
NM-01. Whole body planar and thoracic SPECT/CT scans were performed at 1 and 
2h post-injection in all patients and 5 patients had additional imaging at 10mins, 3 and 
24h for radiation dosimetry calculations. All patients were monitored for adverse 
events. Results: No drug-related adverse events occurred in this study. The mean 
effective dose was 8.84×10-3 ± 9.33×10-4 mSv/MBq (3.59 ±  0.74 mSv per 
patient). Tracer uptake was observed in the kidneys, spleen, liver and bone marrow. 
SPECT primary tumor-blood pool ratios (T:BP) varied from 1.24 to 2.3 (mean=1.79) 
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at 1h and 1.24 to 3.53 (mean=2.22) at 2h (p=0.005). 2h primary T:BP ratios correlated 
with PD-L1 immunohistochemistry results (r=0.68, p=0.014). 2h T:BP was lower in 
tumors with ≤1% PD-L1 expression (1.89 vs 2.49, p=0.048). Nodal and bone 
metastases showed tracer uptake. Heterogeneity (>20%) between primary tumor and 
nodal T:BP was present in 4 of 12 patients. Conclusion: This first in human study 
demonstrates that 99mTc-labeled anti-PD-L1-sdAb SPECT/CT imaging is safe and 
associated with acceptable dosimetry. Tumor uptake is readily visible against 
background tissues, particularly at 2h when the T:BP ratio correlates with PD-L1 
immunohistochemistry results. 
 
 
Key Words: PD-L1; non-small cell lung cancer; SPECT/CT; Early Phase I; Single 
domain antibody (sdAb)  
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality with 
nearly 1.6 million cancer related deaths p.a. worldwide (1). Between 70-80% of patients 
present with unresectable advanced NSCLC at diagnosis and despite the development 
of molecular targeted therapies the prognosis of patients with advanced disease remains 
poor with an overall five-year survival rate of 15% (2,3). The recent breakthrough of 
immunotherapies with checkpoint inhibitor programmed cell death 1 (PD-
1)/programmed death ligand (PD-L1)  antibodies has demonstrated improvements in 
efficacy and tolerability over platinum-based chemotherapy in this subset of patients 
(4-11). Six different PD-1/PD-L1 inhibitors have now been approved by the United 
States Food and Drug Administration for advanced NSCLC  therapy.  
PD-1 receptor, expressed on the surface of activated T-cells, is a negative co-
stimulatory receptor and its ligands, PD-L1 or PD-L2, are normally expressed on the 
surface of dendritic cells or macrophages (12,13). Certain malignancies have developed 
the ability to co-opt these immune checkpoints and escape the T-cell induced antitumor 
activity by overexpressing PD-L1 (14,15).  
Discrepancies in treatment response have highlighted potential deficiencies in 
the current methods to evaluate PD-L1 expression in a clinical setting (16). 
Immunohistochemical assessment of tumor samples obtained by core needle biopsy is 
often unable to capture the heterogeneity and dynamic nature of PD-L1 expression 
within the tumor and its microenvironment (17). In addition, core needle biopsy is not 
always practical (e.g. in patients with widespread metastatic or skeletal involvement) 
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or may be of too high risk to be performed (e.g. certain mediastinal metastases). With 
the advent of immunotherapies, there is a need to develop a non-invasive imaging 
strategy to evaluate PD-L1 expression for optimal treatment stratification and 
monitoring.  
Single domain antibodies (sdAbs) are the smallest naturally derived antigen-
binding fragments from camelid antibodies and demonstrate great potential for 
molecular imaging in both preclinical and clinical models (18-21). Due to their low 
molecular weight (ca. 15 kDa) sdAbs rapidly clear from the circulation via the kidneys 
while retaining high target-binding potential.  We developed a library of hexahistidine 
tagged anti-PD-L1 sdAbs that specifically bind to human PD-L1 without blocking PD-
1/PD-L1 interaction. Due to them being designed to bind to a different domain of PD-
L1, anti-PD-L1 immunotherapeutics will be unlikely to interfere with the binding of 
anti-PD-L1 sdAbs to PD-L1, thereby potentially allowing close monitoring of anti-PD-
L1 immunotherapy by imaging. Recent studies demonstrated the potential of sdAbs for 
nuclear medicine imaging (22) . 
Our hypothesis was that single photon emission computed tomography (SPECT) 
imaging of NSCLC with a 99mTc-labeled sdAb (99mTc-NM-01) that specifically binds 
to human PD-L1 is feasible, safe and correlates with PD-L1 immunohistochemistry 
results. In this first in human study we aimed to assess safety, radiation dosimetry and 
imaging characteristics of 99mTc-NM-01 and sought to compare imaging and PD-L1 
immunohistochemistry results in patients with advanced NSCLC. 
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MATERIALS AND METHODS 
This was an open-label, non-randomized early phase I diagnostic study in 
patients with untreated NSCLC (n = 16) between March and November 2018 
(ClinicalTrials.gov identifier no. NCT02978196) and obtained approval from Shanghai 
General Hospital Ethics Committee (Approval Number: 2016KY220). All patients 
enrolled into this study gave written informed consent in order to participate. 
All materials used in the synthesis of 99mTc-NM-01 were prepared to good 
manufacturing practice standards. For details of anti-PD-L1 sdAb production, 
radiolabeling and quality control refer to Supplemental Materials. Briefly, to radiolabel 
NM-01 the [99mTc(OH2)3(CO)3]
+ complex (pH 7.0-7.5) was added to a sealed vial 
containing 200 µg NM-01 in 100 µl phosphate buffered saline (pH 7.4) and the mixture 
was incubated at 37°C for 1 hour (23-25). Contents were diluted in physiological saline; 
in patient group 2 (see below), to adjust the injected dose to 400 µg per patient, 
additional NM-01 was added in this step.  
Patients aged between 18 and 75 years with histopathologically confirmed 
NSCLC and Eastern Cooperative Oncology Group Performance Score (ECOG) of ≤1 
were eligible to participate in this study (Supplemental Fig. 1). PD-L1 expression was 
determined in primary tumor tissue obtained by core needle biopsy. Details of 
immunohistochemistry sample preparation and processing are reported in 
Supplemental Materials.  
Patients received a single intravenous injection of 99mTc-NM-01 (3.8-10.4 
MBq/kg), corresponding to 100 µg (group 1, n=13, 1.7 ±  0.3 µg/kg, range 1.2-2.1 
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µg/kg) or 400 µg (group 2, n=3, 5.9 ± 0.3 µg/kg, range 5.6-6.1 µg/kg), of NM-01. 
Whole body planar and thoracic tomographic imaging was performed on a GE 
Discovery NM07 SPECT/CT scanner (GE Healthcare, China) 1h and 2h after injection 
in all patients. One patient with known skeletal metastases had additional SPECT/CT 
acquisitions to include these sites. Adverse events were observed by monitoring vital 
signs, physical examination and clinical laboratory tests for each patient during a 
follow-up period of 7 days. Details of scanning protocol and monitoring of adverse 
events are reported in Supplemental Materials.  
All scans were assessed by a single observer (GJRC) with over 25 years of 
nuclear medicine and radiology experience. Maximum counts were recorded from 
regions of interest (ROIs) drawn manually on SPECT scans, using the CT for guidance, 
around the primary tumor, any lymph node metastases within the thoracic field of view, 
a 3cm normal lung ROI in the right upper lobe (or left upper lobe if pathology existed 
in the right upper lobe) for tumor to lung ratios (T:L) and a ROI, within the aortic arch 
avoiding the walls of the aorta, for calculation of tumor to blood pool ratios (T:BP). 
Radiation Dosimetry Calculations 
Five patients underwent additional whole body planar imaging at 10min, 3h and 
24h post-injection, to obtain radiation dosimetry data. No corrections were made for 
attenuation within the patient. A calibration source of 37 MBq at injection time was 
placed above the head of each patient to provide quantitative calibration of counts to 
activity. Radiation dosimetry calculations were performed by an experienced operator 
(JOD) in OLINDA/EXM dose calculation software (version 1.1) using well-known 
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models (26,27). Imaging protocol and radiation dosimetry calculations are reported in 
Supplemental Materials. 
Statistics 
Differences and correlations between parameters were tested using the 
Wilcoxon signed rank test, Mann-Witney U-test and Spearman’s correlation using IBM 
SPSS Statistics Version 24 software. A p value of <0.05 was taken for statistical 
significance. 
 
RESULTS 
Average radiochemical purity (RCP) of radiolabeled NM-01 was 96.9 ± 0.9% 
(95.4% - 98.5%), purification after radiolabeling was not necessary (Supplemental 
Fig. 2). Endotoxin levels remained below 0.4 EU/ml.  
Patient Characteristics 
16 patients (11 male, mean age 61.7 years) with histopathologically proven 
NSCLC (9 squamous cell carcinoma, 7 adenocarcinoma) were included. Clinical stage 
and other characteristics are summarized in Table 1. Uptake in lymph node metastases 
was observed in 12 patients. PD-L1 expression determined by immunohistochemistry 
ranged from 0 to 85% (Supplemental Fig. 3). The mean administered activity of 99mTc-
NM-01 was 372 ± 62 MBq (range 255-485 MBq) in group 1 and 659 ± 25 MBq (range 
635-685 MBq) in group 2 (Table 1). 
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Safety Assessment 
99mTc-NM-01 was administered in 16 patients, no drug related adverse reactions 
were reported during the seven-day follow-up period. Symptoms related to advanced 
stage lung cancer, i.e. frequent coughing, dyspnea and fatigue, reported by some 
patients were not attributed to the radiopharmaceutical by the supervising physician 
(GC). Blood and urine clinical laboratory tests performed in the follow-up period were 
in the normal range of National Cancer Institute - Common Toxicology Criteria for 
Adverse Events version 4.0 standards. There were no significant changes recorded in 
clinical parameters such as heart rate, respiratory rate, body temperature and blood 
pressure during the follow-up. After participating in this study, patients proceeded with 
their treatment regimen.  
Biodistribution 
Tracer biodistribution in normal organs reflected physiological expression of 
PD-L1, with uptake observed in the lungs, liver, spleen and bone marrow (Fig. 1) 
(28,29). Activity in these organs reduced with time and, in particular, lung and blood 
pool activity reduced between 1 and 2h in all patients allowing increased tumor to 
background conspicuity at 2h. Early diffuse lung activity that subsequently reduces may 
be as a result of a combination of blood pool and marginating immune cell activity (30). 
Renal activity persisting over 24h reflects excretion and possible renal tubular retention 
(Fig. 1). 
No noticeable differences in image quality and no statistically significant differences 
in tumor to background ratio were observed between group 1 and group 2 (Fig. 1). 
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Radiation Dosimetry  
Table 2 summarizes individual organ doses and effective doses for patients 
included in the dosimetry study (n=5). All patients had normal liver and kidney 
functions. The kidneys showed the highest organ dose (0.036 ± 0.018 mSv/MBq), 
followed by the bladder (0.026 ± 0.011 mSv/MBq), spleen (0.022 ± 0.011 mSv/MBq), 
and liver (0.011 ± 0.0025 mSv/MBq) and in line with the uptake and excretory pathway 
of the imaging agent. Time activity curves for organs with highest radiotracer uptake 
are shown in Figure 2.  
Tumor activity and relationship with PD-L1 Immunohistochemistry 
Primary tumor T:L ratio was greater at 2h than 1h (mean 2.69 vs 2.22, p=0.034) 
allowing reasonably good tumor conspicuity against normal background lung activity 
in patients with high PD-L1 expression (Fig. 3; Table 3). Primary tumor T:BP ratio was 
also greater at 2h (mean 2.22 vs 1.79, p=0.005). Intratumoral heterogeneity of tracer 
uptake was noted in some primary tumors (Fig. 4). Patients with PD-L1 expression ≤ 
1%, a level often used to stratify patients, showed significantly lower T:BP ratios (mean 
1.89 vs 2.49, p=0.048). By receiver operating characteristic (ROC) analysis this gives 
an optimal threshold for 2h TBP of 2.32 (area under ROC = 0.88).  
Thoracic lymph node metastases T:BP ratios were also greater at 2h although this 
difference did not reach statistical significance (mean 2.02 vs 1.83, p=0.12). At 2h, 
primary tumor and maximum lymph node metastasis T:BP ratios (n=12) showed a 
correlation (r=0.69, p=0.013). Intra-patient heterogeneity of T:BP ratios was noted 
between the primary tumor and lymph node metastases in several patients with a mean 
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difference of 19% (± 17%), with 4 out of the 12 patients with lymph node metastases 
showing a greater than 20% difference (Fig. 5). If a 2h T:BP of 2.32 is used as a 
threshold for positivity, then only 3 out of the 13 patients with nodal disease would 
have been PD-L1 positive on SPECT. One patient with known bone metastases showed 
99mTc-NM-01 uptake (Fig. 6). Primary tumor T:BP ratios at 2h correlated with PD-L1 
immunohistochemistry results (r=0.68, p=0.014). Statistically significant correlations 
were not found for T:L ratios or 1h T:BP ratios.  
 
DISCUSSION 
This early phase 1 study demonstrates that 99mTc-NM-01 SPECT/CT imaging 
is a safe procedure, with no adverse events due to the radiopharmaceutical recorded in 
this cohort of patients. We achieved reproducibly high RCP in labeling NM-01. 
Radiation dosimetry is acceptable at 8.84×10-3 ± 9.33×10-4 mSv/MBq  (3.59 ±  0.74 
mSv per patient) and similar to other SPECT agents in clinical use. The kidneys 
received the highest organ dose (0.036 ± 0.018 mSv/MBq) being the major route of 
excretion and although it remained tolerable, urinary tract dose could be further 
minimized by good hydration or co-injection of amino-acids or peptides (31). 
Patients were administered either 100 µg or 400 µg of protein to explore specific 
binding in the liver and spleen, but no significant impact was observed in image quality 
or organ biodistribution. No statistically significant differences were noted in tumor to 
background ratios between the groups, therefore, subsequent studies were performed 
with 100 µg. 
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Biodistribution was as expected with early activity in the liver, spleen and 
kidneys and some activity in the lungs and bone marrow (28). Rapid renal excretion 
allowed reduction of non-specific background blood pool and organ activity and 
enabled imaging at relatively early time points. In particular, rapid reduction in normal 
lung and blood pool activity allowed sufficient conspicuity of primary NSCLC and 
metastases on SPECT imaging. Imaging characteristics were more favorable at 2h post-
injection compared to 1h due to reduction in lung and blood pool activity over this time. 
Measurement of PD-L1 expression by immunohistochemistry is currently the 
method patients are stratified with for anti-PD-1/PD-L1 immunotherapy. Due to the 
heterogeneity of PD-L1 expression in lung cancers, biopsy material from one region of 
a tumor may not allow global or other regional assessment of PD-L1 expression (32). 
The underestimation of PD-L1 expression by sampling error in heterogenous tumors 
may be one of the reasons that apparent PD-L1 negative tumors respond to PD-1/PD-
L1 checkpoint inhibitor therapy (33-35). Immunohistochemical evaluation is also 
limited by practicality and safety of multiple biopsies in patients with metastatic disease. 
Relying on immunohistochemistry results from tissue biopsy also limits the practicality 
of observing the evolution of PD-L1 expression in primary and metastatic tumors 
during therapy. For these reasons, a non-invasive imaging method that is safe and 
associated with low radiation dose, that can accurately report locoregional PD-L1 
expression in primary tumors and metastases at serial time points, would be a valuable 
tool for guiding clinical management of patients with PD-L1 positive malignancies. 
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The use of 99mTc with a half-life of 6 hours and a straightforward site-specific 
labeling technique for NM-01 would allow distribution from centralized 
radiopharmacies as well as on-site labeling at any standard hospital radiopharmacy 
enabling widespread use of this methodology. There would also be future potential for 
labeling with PET radionuclides to help improve image spatial resolution, contrast and 
quantification (32). 
Our intial results show promise that the simple measurement of T:BP ratios at 
2h correlates with PD-L1 expression and if confirmed in subsequent studies could 
potentially replace or complement immunohistochemistry in some circumstances. We 
noted heterogeneity of activity within primary tumors in some patients, and between 
the primary tumor and metastases within patients, suggesting that intra- and inter-
tumoral heterogeneity of PD-L1 expression is relatively common and is another factor 
that could be measured non-invasively with imaging to allow more relevant information 
to be available for patient treatment decisions. Intra-tumoral PD-L1 expression 
heterogeneity may also explain the imperfect correlation with T:BP (r=0.68). 
A potential limitation of this study is the relatively small number of patients 
that were included, although it is similar to other phase 1 studies of 
radiopharmaceuticals and has sufficient power to allow statistical comparisons of 
optimal imaging time, radiodosimetry calculations and correlations with 
immunohistochemistry results. Immunohistochemical analysis was not available in all 
patients and only primary tumors were assessed therefore not allowing comparison 
between imaging and PD-L1 expression in nodal and distant metastases. SPECT 
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images were acquired for up to 2 hours post-injection in all patients. To determine 
whether image characteristics (i.e. target-to-background) could be improved, further 
scanning beyond 2 hours could be considered in subsequent studies. The relatively 
low spatial resolution of SPECT does not allow more than gross visual intratumoral 
heterogeneity observations. Although a PET tracer, in theory might allow more 
accurate and detailed heterogeneity analysis similar to what has been reported with 
18F-FDG PET/CT in NSCLC (36), recent studies with an anti-PD-L1 tracer for PET 
also reported on insufficient spatial resolution (32). In addition, we have only 
examined NSCLC in this study and cannot extrapolate these results to other 
malignancies that are known to express PD-1/PD-L1. 
 
CONCLUSION 
This study demonstrates that 99mTc labeled anti-PD-L1-sdAb SPECT/CT using 
99mTc-NM-01 is a safe diagnostic procedure delivering a tolerable radiation dose, and 
presenting favorable biodistribution and image chacteristics correlating with PD-L1 
immunohistochemistry results in patients with NSCLC. As PD-1/PD-L1 immune 
checkpoint inhibitors are more frequently used in the treatment of NSCLC, a 
companion imaging methodology is becoming increasingly sought-after for the staging 
and monitoring of patients. Anti-PD-L1-sdAb SPECT/CT using 99mTc-NM-01 has the 
potential to be used for the close monitoring of changes in PD-L1 expression levels 
during PD-L1 immunotherapy.  In addition, the heterogeneous and dynamic nature of 
PD-L1 expression in most malignancies could make imaging a preferred method 
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compared to more invasive core needle biopsies in diagnosing and staging patients with 
PD-L1 positive malignancies.  
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Figure Legends 
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FIGURE 1. (A) anterior whole body images 10mins, 1, 2, 3 and 24hrs post-injection 
of a patient administered with 100 g (group 1) and (B) 1 and 2h images of a patient 
administered with 400 g of NM-01 (group 2). No significant difference in 
biodistribution was seen between the two groups. 
 
 
FIGURE 2. Time activity curves for organs with highest radiotracer uptake. 
 22 
 
 
 
FIGURE 3. (A) Left upper lobe tumor T:BP = 3.12 (PD-L1 expression 50%), (B) left 
upper lobe tumor T:BP = 2.26 (PD-L1 expression 0%). 
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FIGURE 4. A left upper lobe tumor showing heterogeneity of PD-L1 expression. 
Central photopoenia is in keeping with necrosis but there is heterogeneity of uptake in 
the solid peripheral component of the tumor (T:BP = 2.46, PD-L1 expression 85%). 
 
 
 
FIGURE 5. A right upper lobe tumor (open arrows) shows areas of high FDG uptake 
(SUVmax = 16.1) on PET/CT (A) and 99mTc-SPECT/CT (T:BP = 3.53) (B). 
Mediastinal lymph nodes (closed arrows) show high FDG uptake (SUVmax = 6.3) (C) 
but low 99mTc-NM-01 activity (T:BP = 1.13) (D) demonstrating heterogeneity of PD-
L1 expression between primary tumor and nodal sites of disease within the same patient. 
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FIGURE 6. Coronal (A) and axial (B) 99mTc-NM-01 SPECT/CT images of a patient 
with skeletal metastases (arrows) demonstrating PD-L1 expression. 
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Tables 
Table 1: Patient Characteristics 
Dose Group Patient 
No. 
Age Gender Tumor Type Tumor Size 
(CT axial 
dimensions) 
Clinical 
Staging 
PD-L1 
Expression 
(%) 
ECOG 
Score 
Group 1 
3.8-8.4 MBq/kg-  
1.2-2.1 µg/kg 
1 49 Male Adenocarcinoma 37*27mm cT4N3M1 IV NA 1 
2 75 Male Squamous Cell Carcinoma 44*48mm T3N3M1 IV 20 1 
3 75 Male Squamous Cell Carcinoma 55*46mm T2bN3M0 
IIIB 
0 1 
Group 2 
9.1-10.4 MBq/kg- 
5.6-6.1 µg/kg 
4 65 Male Adenocarcinoma 48*42 mm  T2bN3M1 IV 0 0 
5 57 Male Squamous Cell Carcinoma 32*35 mm cT2N2M0  
IIIA 
 
55 0 
6 65 Male Squamous Cell Carcinoma 30*58 mm T2aN2M0 
IIIA 
3 0 
 
 
Group 1 
3.8-8.4 MBq/kg-  
1.2-2.1 µg/kg 
7 75 Female Adenocarcinoma 38*28mm T2aN0M0 NA 0 
8 52 Female Squamous Cell Carcinoma 33*23mm T2aN0M0 1B 0 0 
9 36 Female Adenocarcinoma 45*35mm T2aN2M1 IV 1 1 
10 46 Female Adenocarcinoma 42*35mm T3N1M0 IIIA 50 0 
11 51 Male Squamous Cell Carcinoma 47*35mm T2aN3M0 
IIIB 
2 0 
12 72 Male Adenocarcinoma 46*53mm T2bN3M1 IV NA 1 
13 55 Male Squamous Cell Carcinoma 71*78mm T4N0M1c IV 85 0 
14 69 Male Squamous Cell Carcinoma 20*28mm T3N1M0 IIIA 10 0 
15 71 Female Squamous Cell Carcinoma 78*95mm T4N1M1a IV NA 1 
16 60 Male Adenocarcinoma  93*75mm T4N3M1a IV 2 0 
*NA= not available 
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Table 2: Organ Radiation Doses 
 
Organ/tissue 
Mean 
(mSv/MBq) 
SD 
(mSv/MBq) 
Adrenals 5.54E-03 1.80E-03 
Brain 1.41E-03 4.15E-04 
Breasts 1.66E-03 5.86E-04 
Gallbladder 4.89E-03 1.69E-03 
Lower large intestine wall 4.00E-03 9.79E-04 
Small intestine 3.88E-03 1.13E-03 
Stomach 6.04E-03 1.71E-03 
Upper large intestine wall 3.72E-03 1.15E-03 
Heart wall 3.17E-03 1.04E-03 
Kidneys 3.60E-02 1.76E-02 
Liver 1.10E-02 2.51E-03 
Lungs 4.53E-03 1.23E-03 
Muscle 2.62E-03 8.35E-04 
Ovaries 4.11E-03 1.01E-03 
Pancreas 5.72E-03 2.01E-03 
Red Marrow 6.73E-03 3.25E-03 
Osteogenic cells 8.08E-03 1.74E-03 
Skin 1.49E-03 5.46E-04 
Spleen 2.21E-02 1.14E-02 
Testes 2.44E-03 8.40E-04 
Thymus 2.32E-03 7.89E-04 
Thyroid 4.00E-03 2.25E-02 
Urinary Bladder wall 2.58E-02 1.05E-02 
Total body 3.20E-03 9.13E-04 
Effective Dose 8.84E-03 9.33E-04 
 
Table 2: Radiation absorbed doses calculated by OLINDA/EXM software and overall 
effective dose (mSv/MBq) (n=5). 
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Table 3: Imaging characteristics 
 
Patient 
no. 
sdAb 
dose 
group 
Injected 
activity 
(MBq) 
SPECT 
T:L 
ratio 
1h 
SPECT 
T:L 
ratio 
2h 
SPECT 
T:BP 
ratio 
1h 
SPECT 
T:BP 
ratio 
2h 
SPECT 
highest 
lymph 
node 
T:BP 
ratio 
1h 
SPECT 
highest 
lymph 
node 
T:BP 
ratio 
2h 
1 1 339 1.92 2.17 1.31 1.24 1.84 1.64 
2 1 374 2.82 2.99 2.03 3.09 1.99 3.40 
3 1 375 2.16 2.80 1.25 1.65 1.31 1.73 
4 2 656 1.19 1.44 1.24 1.66 1.43 1.73 
5 2 685 0.93 1.10 2.23 2.65 1.65 1.95 
6 2 635 2.71 1.88 1.75 1.79 2.22 3.24 
7 1 255 1.80 2.06 1.31 1.76 NP NP 
8 1 398 2.48 2.41 1.83 2.26 NP NP 
9 1 486 1.42 2.07 1.95 2.00 2.1 1.9 
10 1 381 3.15 5.63 2.13 3.12 1.47 1.75 
11 1 317 1.92 1.74 1.73 2.37 1.39 2.26 
12 1 448 4.17 6.50 2.20 3.53 3.05 3.13 
13 1 400 2.4 3.09 1.61 2.46 NP NP 
14 1 409 1.49 1.54 1.68 1.98 1.75 1.34 
15 1 289 1.69 1.47 2.16 1.55 1.9 1.77 
16 1 363 3.35 4.15 2.3 2.47 2.23 2.09 
Mean   2.22 2.69 1.79 2.22 1.83 2.02 
Median   2.04 2.12* 1.79 2.13** 1.84 1.77+ 
Table 3: T:L primary tumor to lung ratio, T:BP primary tumor to blood pool ratio, 
*p=0.034 between 1 and 2h, **p=0.005 between 1 and 2h, +p=Not Significant; NP= 
not present 
 
 
 
 
 
 
